OS Therapies Incorporated (NYSE MKT:OSTX) — Market Cap & Net Worth
Market Cap & Net Worth: OS Therapies Incorporated (OSTX)
OS Therapies Incorporated (NYSE MKT:OSTX) has a market capitalization of $42.96 Million ($42.96 Million) as of July 22, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #22441 globally and #4902 in its home market, demonstrating a -7.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OS Therapies Incorporated's stock price $1.73 by its total outstanding shares 35214352 (35.21 Million). Review OSTX total debt and obligations to assess the company's total debt and financial obligations.
OS Therapies Incorporated Market Cap History: 2024 to 2026
OS Therapies Incorporated's market capitalization history from 2024 to 2026. Data shows change from $150.72 Million to $60.92 Million (-18.63% CAGR).
OS Therapies Incorporated Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OS Therapies Incorporated's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OSTX by Market Capitalization
Companies near OS Therapies Incorporated in the global market cap rankings as of July 22, 2026.
Key companies related to OS Therapies Incorporated by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #560 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $480.50 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $672.15 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €753.60 |
| #560 | UCB SA | BR:UCB | $47.34 Billion | €238.00 |
OS Therapies Incorporated Historical Marketcap From 2024 to 2026
Between 2024 and today, OS Therapies Incorporated's market cap moved from $150.72 Million to $ 60.92 Million, with a yearly change of -18.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $60.92 Million | +23.57% |
| 2025 | $49.30 Million | -67.29% |
| 2024 | $150.72 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 21st, 2026 the market cap of OS Therapies Incorporated was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $42.96 Million USD |
| MoneyControl | $42.96 Million USD |
| MarketWatch | $42.96 Million USD |
| marketcap.company | $42.96 Million USD |
| Reuters | $42.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide lin… Read more